MSLN and pancreatic neoplasm: This highlighted the need for additional cancer-specific promoters that target (i) a greater proportion of pancreatic cancers, and (ii) particularly the most lethal ones, possibly suggesting a combined approach with MSLN promoter-driven DT-A (as well as other specific promoter-driven constructs) in a multitargeted therapeutic approach that might be required to overcome tumor recurrence [25].